Notably, Chidamide treatment also significantly impacted genes related to MAPK signaling, PI3K/AKT signaling, mTOR signaling, and Wnt signaling, suggesting potential mechanisms for DLBCL treatment with Chidamide (Fig. 4e). This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.